Abstract
Lewy bodies are pathological hallmarks for the diagnosis of Parkinson’s disease, where the core components are composed of aggregated forms of α-synuclein (α-syn). Although α-syn has been investigated as a potential biomarker for PD, its usage has been limited and still remains controversial. An accurate enzyme-linked immunosorbent assay (ELISA) was developed for the detection of α-syn in plasma. The hemolysis score was calculated to eliminate the additive α-syn levels from RBCs. Human plasma samples were collected in heparinized blood tubes from idiopathic Parkinson disease (IPD) and healthy control (HC). Hemolysis score had a strong correlation with the level of plasma α-syn. From the limited set of samples in this preliminary study, decreased α-syn concentrations were observed in patients with IPD in comparison to HC after adjusting for hemolysis factor. Similar results with a commercial ELISA kit were found for measuring α-syn from the same set of samples with lower correlation and the reduced accuracy of diagnosis than the current study. The adjustments for the hemolysis factor would be indispensable, supporting plasma α-syn as a potential surrogate biomarker for distinguishing IPD from HC.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
